AP1903Homodimer binding to FKBP CAS# 195514-63-7 |
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 195514-63-7 | SDF | Download SDF |
PubChem ID | 16135625 | Appearance | Powder |
Formula | C78H98N4O20 | M.Wt | 1411.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Rimiducid | ||
Solubility | DMSO : 50 mg/mL (35.42 mM; Need ultrasonic) | ||
Chemical Name | [(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate | ||
SMILES | CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC | ||
Standard InChIKey | GQLCLPLEEOUJQC-ZTQDTCGGSA-N | ||
Standard InChI | InChI=1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)/t57-,58-,59-,60-,61+,62+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | AP1903 is a homodimer binding to FKBP, elicits potent and dose-dependent apoptotic death of engineered cell line HT1080 in culture with an EC50 of 0.1 nM. AP1903 induces Fas activation. Fas receptor also known as tumor necrosis factor receptor superfamily member 6 (TNFRSF6).In Vitro:The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. AP1903 elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ≈0.1 nM[1]. Maximal killing occurred in the presence of 3 to 10 nM AP1903, and the IC50 is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after AP1903 treatment[2].In Vivo:AP1903 (i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum hGH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg[1]. References: |
Kinase experiment [1]: | |
FKBP Binding Assay | Subsaturating concentrations of protein were incubated for 30 min with 2.5 nM fluoro-FK506 and serial dilutions of competitor ligand in the wells of a Dynatech microfluor plate. Polarization was read on a Jolley FPM-2 (Jolley Consulting and Research, Grayslake, IL). The increase in polarization on binding was used as a direct readout of percentage of bound probe, compared with controls containing no competitor (100%) or no protein (0%). The concentration of competitor resulting in a 50% probe displacement (IC50) was determined by a nonlinear least square fit by using the four-parameter algorithm. |
Cell experiment [1]: | |
Cell lines | Cloned HT1080 cell lines (ATCC CCL-121) |
Preparation method | Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 37oC |
Applications | The human fibrosarcoma line HT1080 was engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human Fas intracellular domain. AP1903 elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ≈0.1 nM. |
Animal experiment [1]: | |
Animal models | Male nu/nu mice |
Dosage form | intravenous injection at 0.01-100 mg/kg |
Preparation method | Formulated in [50% N,N-dimethylacetamide/50% (90% PEG-400/10% Tween 80)] at 2 ml/kg |
Application | Male nu/nu mice were injected with HT1080 cell line expressing a Fas-F36V-FKBP construct that also constitutively secretes hGH. AP1903 exhibits a dose-dependent decrease in serum hGH levels, with a half-maximal effective dose of 0.4 ± 0.1 mg/kg. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: 1. Clackson T, Yang W, Rozamus LW et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42 |
AP1903 Dilution Calculator
AP1903 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 0.7084 mL | 3.542 mL | 7.084 mL | 14.168 mL | 17.71 mL |
5 mM | 0.1417 mL | 0.7084 mL | 1.4168 mL | 2.8336 mL | 3.542 mL |
10 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL | 1.4168 mL | 1.771 mL |
50 mM | 0.0142 mL | 0.0708 mL | 0.1417 mL | 0.2834 mL | 0.3542 mL |
100 mM | 0.0071 mL | 0.0354 mL | 0.0708 mL | 0.1417 mL | 0.1771 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 5 nM for F36V-FKBP in competition fluorescence polarization assay
FKBP ligand homodimers can be used to trigger signaling events inside cells and animals that have been engineered to express fusions between and FKBP appropriate signaling domains. However, use of these dimerizers in vivo is potentially limited by ligand binding to endogenous FKBP. AP1903 is a homodimer of the modified ligand for FKBP.
In vitro: By selective inhibition of FKBP, AP1903 elicited potent and dose-dependent apoptotic death of the human fibrosarcoma line HT1080 engineered cells in culture, with an EC50 of ~0.1 nM [1].
In vivo: In an mouse model of conditional cell ablation, animals were i.v. treated with various doses of AP1903, and then serum hGH levels were determined as a measure of the number of surviving cells. Results showed that AP1903 elicited a dose-dependent decrease in levels of serum hGH, with a half-maximal effective dose of 0.4 mg/kg [1].
Clinical trials: In an intravenous, single-blind, placebo- and saline-controlled, ascending-dose study, AP1903 was shown to be safe and well tolerated at all dose levels and demonstrated a favorable PK profile at doses well above the anticipated therapeutic dose [2].
References:
[1] Clackson T, Yang W, Rozamus LW, Hatada M, Amara JF, Rollins CT, Stevenson LF, Magari SR, Wood SA, Courage NL, Lu X, Cerasoli F Jr, Gilman M, Holt DA. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42.
[2] Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T, Berger HJ. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001 Aug;41(8):870-9.
- Chiirirhamnin
Catalog No.:BCN3179
CAS No.:195450-50-1
- Wortmannin
Catalog No.:BCC3874
CAS No.:19545-26-7
- Bay 11-7821(BAY 11-7082)
Catalog No.:BCC2244
CAS No.:19542-67-7
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Alphitolic acid
Catalog No.:BCN1189
CAS No.:19533-92-7
- Galantamine hydrobromide
Catalog No.:BCN2869
CAS No.:1953-04-4
- Tiopronin (Thiola)
Catalog No.:BCC3870
CAS No.:1953-02-2
- GLP-2 (rat)
Catalog No.:BCC5892
CAS No.:195262-56-7
- N-(3-Methoxybenzyl)oleamide
Catalog No.:BCC6942
CAS No.:883715-21-7
- 4-DAMP
Catalog No.:BCC6661
CAS No.:1952-15-4
- Dihydrosenkyunolide C
Catalog No.:BCC8942
CAS No.:195142-72-4
- 4-Hydroxycinnamamide
Catalog No.:BCN1188
CAS No.:194940-15-3
- Piromidic Acid
Catalog No.:BCC3840
CAS No.:19562-30-2
- Methyl 4-O-feruloylquinate
Catalog No.:BCC9041
CAS No.:195723-10-5
- 2,16,19-Kauranetriol 2-O-beta-D-allopyranoside
Catalog No.:BCN1510
CAS No.:195723-38-7
- (+-)-Byakangelicin
Catalog No.:BCN5000
CAS No.:19573-01-4
- Atrasentan hydrochloride
Catalog No.:BCC1380
CAS No.:195733-43-8
- 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside
Catalog No.:BCN1509
CAS No.:195735-16-1
- HTMT dimaleate
Catalog No.:BCC6736
CAS No.:195867-54-0
- (R)-Nepicastat HCl
Catalog No.:BCC4315
CAS No.:195881-94-8
- 25S-Inokosterone
Catalog No.:BCN3873
CAS No.:19595-18-7
- 17 alpha-propionate
Catalog No.:BCC1296
CAS No.:19608-29-8
- Angelol A
Catalog No.:BCN8036
CAS No.:19625-17-3
- Indole-3-acrylic acid methyl ester
Catalog No.:BCN1190
CAS No.:19626-92-7
Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers.[Pubmed:11504275]
J Clin Pharmacol. 2001 Aug;41(8):870-9.
AP1903 is a novel gene-targeted drug that is being developed for use in drug-regulated cell therapies. An intravenous, single-blind, placebo- and saline-controlled, ascending-dose study was performed to evaluate the safety, tolerability, and pharmacokinetics of AP1903. Twenty-eight normal healthy male volunteers were randomized into five dosage groups of AP1903 (0.01, 0.05, 0.1, 0.5, and 1 mg/kg). Within each group, 4 volunteers received a single dose of AP1903, 1 volunteer received an equal volume of placebo, and 1 received an equal volume of normal saline. The only exception was in the 0.5 mg/kg group, in which 4 volunteers were dosed: 3 received AP1903 and 1 received normal saline. All dosages were administered as intravenous infusions over 2 hours. Clinical safety parameters were monitored, and serial blood and urine samples were collected for analysis of AP1903. No drug-related adverse events were observed at any of the dose levels with the possible exception of facial flushing in 1 volunteer at the 1.0 mg/kg dose level. AP1903 plasma levels were directly proportional to the administered dose, with mean Cmax values ranging from approximately 10 to 1,275 ng/mL over the 0.01 to 1.0 mg/kg dose range. Following the infusion period, blood concentrations revealed a rapid distribution phase, with plasma levels being reduced to approximately 18%, 7%, and 1% of the maximal concentration at 0.5, 2, and 10 hours postdose, respectively. AP1903 was shown to be safe and well tolerated at all dose levels and demonstrated a favorable pharmacokinetic profile at doses well above the anticipated therapeutic dose.